Ovarian Neoplasms: all 2,759 studies
Page 18 of 28. Open to participants first (736), then studies with results posted, then the rest; newest registration first within each.
- MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian CancerStatus unknownNCT03916679Phase 1/2
- Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing CancerActive, not recruitingNCT03907852Phase 1/2
- Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal CancerActive, not recruitingNCT03907527Phase 1
- DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal CarcinomaWithdrawnNCT03905902Phase 3
- Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological CancerWithdrawnNCT03902379Not applicable
- Chiauranib in Combination With Chemotherapy in Patients With Ovarian CancerCompletedNCT03901118Phase 2
- A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)Status unknownNCT03899610Phase 2
- A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian CancerStatus unknownNCT03895788Phase 1
- Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)TerminatedNCT03891576Phase 2
- Determination of the Feasibility of Tumoural Somatic Mutations Detection in Blood of Patients With Ovarian CancerCompletedNCT03881683Not applicable
- A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsCompletedNCT03872947Phase 1
- A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer PatientsCompletedNCT03863860Phase 3
- A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid TumorsTerminatedNCT03861403Phase 1
- Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerActive, not recruitingNCT03860272Phase 1
- Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian CancerTerminatedNCT03858166Phase 4
- A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsCompletedNCT03849469Phase 1
- The IGF Axis Involvement in Immune Tumor Microenvironment in Ovarian Cancer and Its Clinical SignificanceStatus unknownNCT03846856
- Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)Active, not recruitingNCT03842982Phase 3
- Clinical Validation of the InterVenn Ovarian CAncer Liquid BiopsyCompletedNCT03837327
- Feasibility of the LUM Imaging System for Peritoneal Surface MalignanciesCompletedNCT03834272Phase 1/2
- Constitution of ex Vivo Ovarian Tumor Models for the Validation of the Interest of Innovative Therapies and the Search for Tumor or Circulating Biomarkers Predictive of Treatment ResponseCompletedNCT03831230
- Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological TumorsStatus unknownNCT03827837Phase 2
- Efficacy and Safety of Paclitaxel for Injection (Albumin-bound) for First-line Chemotherapy of Ovarian CancerStatus unknownNCT03818282Phase 2
- Avelumab Program Rollover StudyActive, not recruitingNCT03815643Phase 3
- The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian CancerStatus unknownNCT03814447Early Phase 1
- 18F-DCFPyL PET/CT in High-grade Epithelial Ovarian Cancer (PET HOC)CompletedNCT03811899Not applicable
- Imaging Study in Advanced Ovarian CancerStatus unknownNCT03808792
- Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian CancerWithdrawnNCT03806049Phase 3
- NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)CompletedNCT03804866Phase 2
- MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian CancerStatus unknownNCT03799913Early Phase 1
- Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian CancerStatus unknownNCT03794778Phase 4
- A Phase I Study of SOR-C13 in Patients With Advanced Solid TumorsCompletedNCT03784677Phase 1
- Continued Access to RXDX-105CompletedNCT03784378Phase 1
- Treg, Th17 Cells, NKT in Epithelial Ovarian TumorCompletedNCT03779399
- Exploring the Potential of Novel Biomarkers Based on Plasma microRNAs for a Better Management of Pelvic Gynecologic TumorsActive, not recruitingNCT03776630Not applicable
- Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)Active, not recruitingNCT03772028Phase 3
- A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.Status unknownNCT03763123Phase 1
- TAK-659 and Paclitaxel in Treating Patients With Advanced Solid TumorsCompletedNCT03756818Phase 1
- Microscopic Peritoneal Metastases After Complete Macroscopic Cytoreductive Surgery for Epithelial Ovarian CancerCompletedNCT03754569Not applicable
- NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.CompletedNCT03752216Phase 4
- Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial CancersCompletedNCT03748186Phase 1
- A Phase 1 Study of [225Ac]-FPI-1434 InjectionTerminatedNCT03746431Phase 1
- A Multi-omics Study of Epithelial Ovarian CancerStatus unknownNCT03742856
- Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian CancerCompletedNCT03742713Phase 2
- A Genomic Analysis of Evolution of Epithelia Ovarian TumorsStatus unknownNCT03742388
- Effects of Music or Hypnotherapy on Cancer Patients During ChemotherapyTerminatedNCT03740984Not applicable
- Long-acting G-CSF for Febrile NeutropeniaStatus unknownNCT03740464Phase 3
- Non-coding RNA in the Exosome of the Epithelia Ovarian CancerStatus unknownNCT03738319
- Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerWithdrawnNCT03735589Phase 1/2
- Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal CarcinomatosisCompletedNCT03732768Phase 1
- A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic MalignanciesCompletedNCT03719326Phase 1
- Hyperthermic Intraperitoneal Chemotherapy for Treatment of Relapsed Ovarian CancerStatus unknownNCT03717610Not applicable
- A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian CancerStatus unknownNCT03709316Phase 3
- Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot StudyCompletedNCT03707574
- Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer PatientStatus unknownNCT03705156Phase 3
- An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)Status unknownNCT03699449Phase 2
- A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian CancerCompletedNCT03695380Phase 1
- Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal CancerStatus unknownNCT03693248Phase 3
- Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian CancerStatus unknownNCT03692637Early Phase 1
- Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT03691376Phase 1
- Circulating Tumour DNA as a Marker of Residual Disease & Response to Adjuvant Chemotherapy in Stage I-IV Ovarian CancerActive, not recruitingNCT03691012
- Study Describing the Coverage, Cares and the Fertility of Patients of Less Than 45 Years With a Borderline Ovarian TumorCompletedNCT03690440
- A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.CompletedNCT03681548Phase 1
- COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.CompletedNCT03667716Phase 1
- DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian CancerCompletedNCT03657966Phase 2
- Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian CancerCompletedNCT03656809
- High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower LimbsCompletedNCT03653819Not applicable
- Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)CompletedNCT03648489Phase 2
- Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian CancerCompletedNCT03639246Phase 1
- Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast CancerWithdrawnNCT03634150Phase 1/2
- Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian CancerWithdrawnNCT03632798Phase 3
- Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO GuidelinesTerminatedNCT03622931Phase 2
- Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian CancerStatus unknownNCT03618706Phase 2
- Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune RepertoireActive, not recruitingNCT03614689
- Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian CancerStatus unknownNCT03611179Phase 2
- Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal CancersCompletedNCT03604653
- Urinary Human Papilloma Virus Test in the General Population in BrittanyTerminatedNCT03598946Not applicable
- Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian CancerCompletedNCT03596281Phase 1
- Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian CancerTerminatedNCT03587129Phase 2
- Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT03586661Phase 1
- Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian CancerCompletedNCT03579394Not applicable
- Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT03579316Phase 2
- SEntine Lymph Node in earLY Ovarian Cancer (SELLY)CompletedNCT03563781Not applicable
- Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial CancerCompletedNCT03562897Phase 2
- Open Label Immunotherapy Trial for Ovarian CancerStatus unknownNCT03556566Phase 2
- The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian CancerCompletedNCT03551171Phase 1
- Clinical Study of Apatinib in the Treatment of Advanced Ovarian Cancer After the Failure of Standard ChemotherapyStatus unknownNCT03547375Phase 2
- Diaphragmatic Resection And Gynecological Ovarian NeoplasmCompletedNCT03543462Phase 4
- Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian CancerStatus unknownNCT03542669Phase 1
- Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma PatientsCompletedNCT03539406Phase 1
- Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian CancerStatus unknownNCT03539328Phase 2
- Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum ChemotherapyCompletedNCT03534453Phase 3
- Molecular Imaging and Spectroscopy With Stable Isotopes in Oncology and NeurologyStatus unknownNCT03526809
- Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian CancerActive, not recruitingNCT03519230Phase 3
- Restrictive or Individualized Goal-Directed Fluid Replacement Strategy in Ovarian Cancer Cytoreductive SurgeryCompletedNCT03519165Not applicable
- A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian CancerCompletedNCT03509636Phase 1
- Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer PatientsStatus unknownNCT03509246Phase 2
- Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal CarcinomatosisCompletedNCT03508570Phase 1
- A Study of IMP4297 in Patients With Advanced Solid TumorsCompletedNCT03508011Phase 1
- The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid TumorsCompletedNCT03507543Phase 1